Literature DB >> 12377391

Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration.

Colin Davidson1, Tong H Lee, Zhiping Xiong, Everett H Ellinwood.   

Abstract

Male Sprague-Dawley rats were given two separate sensitizing regimens of cocaine (7 days on, 7 days off, 7 days on; 40 mg/kg/day s.c.) along with saline controls. Furthermore, animals also received the 5-HT(3) antagonist ondansetron (0.2 mg/kg s.c.) either during the second dosing regimen (3.5 h after each cocaine/saline injection) or during the first five days of the second withdrawal period. Animals were then challenged, on day 10 of withdrawal, with cocaine (7.5 mg/kg i.p.) and assessed by a behavioral rating scale and locomotor activity monitoring. The cocaine regimen induced behavioral and locomotor sensitization on day 10 of withdrawal, further, ondansetron inhibited sensitization regardless of whether given after each second cocaine regimen dose or during the second withdrawal period, although treatment 3.5 h after each cocaine injection appeared more effective. Ondansetron did not inhibit behavior in control animals. In a second experiment animals were trained to self-administer cocaine via an indwelling jugular catheter. After stable fixed-ratio responding (FR1 then FR2) they were given a progressive ratio (PR) schedule until PR each day was stable. During the first five days of withdrawal they were given either ondansetron (0.2 mg/kg s.c.) or saline injections. On day 10 of withdrawal the cocaine PR schedule was reinstated. The ondansetron treated rats showed only a non-significant decrease in break point. After day 2 of the PR session rats were again injected with either ondansetron (0.2 mg/kg s.c.) or saline, 3.5 h after each PR session for five days. Ondansetron inhibited cocaine self-administration on each of the following days. Ondansetron may be a useful treatment for cocaine addicts who have undergone previous sensitization periods.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377391     DOI: 10.1016/S0893-133X(02)00336-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   8.294


  13 in total

Review 1.  Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.

Authors:  Tong H Lee; Steven T Szabo; J Corey Fowler; Paolo Mannelli; O Barry Mangum; Wayne F Beyer; Ashwin Patkar; William C Wetsel
Journal:  Drug Alcohol Depend       Date:  2012-02-21       Impact factor: 4.492

2.  Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients.

Authors:  Ashwin A Patkar; Paolo Mannelli; Kathleen Peindl; Kevin P Hill; Raman Gopalakrishnan; Wade H Berrettini
Journal:  Psychopharmacology (Berl)       Date:  2006-01-17       Impact factor: 4.530

3.  Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine.

Authors:  Kamal S Bhatia; Steven T Szabo; J Corey Fowler; William C Wetsel; Tong H Lee
Journal:  Behav Brain Res       Date:  2011-05-07       Impact factor: 3.332

4.  Differences in regional cerebral blood flow response to a 5HT3 antagonist in early- and late-onset cocaine-dependent subjects.

Authors:  Bryon Adinoff; Michael D Devous; Mark J Williams; Thomas S Harris; Susan E Best; Hongyun Dong; Tanya Zielinski
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

5.  Quinine enhances the behavioral stimulant effect of cocaine in mice.

Authors:  Adriana Huertas; William D Wessinger; Yuri V Kucheryavykh; Priscila Sanabria; Misty J Eaton; Serguei N Skatchkov; Legier V Rojas; Gerónimo Maldonado-Martínez; Mikhail Y Inyushin
Journal:  Pharmacol Biochem Behav       Date:  2014-12-05       Impact factor: 3.533

6.  Integrin-linked kinase is involved in cocaine sensitization by regulating PSD-95 and synapsin I expression and GluR1 Ser845 phosphorylation.

Authors:  Qiang Chen; Xiongzhao Zhu; Yu Zhang; William C Wetsel; Tong H Lee; Xiuwu Zhang
Journal:  J Mol Neurosci       Date:  2009-07-24       Impact factor: 3.444

Review 7.  Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside.

Authors:  Steven M Graves; Roueen Rafeyan; Jeffrey Watts; T Celeste Napier
Journal:  Pharmacol Ther       Date:  2012-08-29       Impact factor: 12.310

Review 8.  Agents in development for the management of cocaine abuse.

Authors:  David A Gorelick; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Time-dependent changes in nicotine behavioral responsivity during early withdrawal from chronic cocaine administration and attenuation of cocaine sensitization by mecamylamine.

Authors:  Steven T Szabo; J C Fowler; Brett Froeliger; Tong H Lee
Journal:  Behav Brain Res       Date:  2014-01-07       Impact factor: 3.352

Review 10.  Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models.

Authors:  B Jupp; J W Dalley
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.